AB-729

DRUG3 trials

Sponsors

Assembly Biosciences, Antios Therapeutics, Inc, Arbutus Biopharma Corporation

Conditions

Chronic Hepatitis BChronic Hepatitis bHepatitis B, ChronicHepatitis D

Phase 2

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

TerminatedNCT04820686

Assembly BiosciencesChronic Hepatitis B

Start: 2021-05-07End: 2023-03-30Updated: 2023-11-14

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

TerminatedNCT04847440

Antios Therapeutics, IncHepatitis B, Chronic, Hepatitis D

Start: 2021-03-30End: 2022-09-01Updated: 2022-11-18

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

CompletedNCT04980482

Arbutus Biopharma CorporationChronic Hepatitis b

Start: 2021-10-29End: 2025-05-21Updated: 2025-10-22

Related Papers

A randomized phase 1b trial of the active site polymerase inhibitor nucleotide <scp>ATI</scp>‐2173 in patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis2022-10-069 citations